CLIMB BIO, INC. (CLYM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 5.93M USD | Liabilities, Current |
| Cash and equivalents | 44.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 139.02M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.93M | $44.11M | $139.02M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.07M | $8.36M | $101.21M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $6.98M | $35.69M | $65.39M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $4.95M | $25.80M | $61.10M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $6.21M | $22.68M | $62.02M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.04M | $29.02M | $69.04M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $4.93M | $87.23M | $63.69M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $3.42M | $146.18M | $47.18M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.74M | $223.14M | $0.00 | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.95M | $105.03M | $0.00 | (m) | (m) | (m) |
| 2023-12-31 | (m) | $2.83M | $93.11M | $13.69M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.90M | $57.35M | $50.08M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $3.62M | $25.29M | $77.34M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.92M | $34.44M | $74.94M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.10M | $43.59M | $79.98M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.28M | $35.94M | $86.67M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $7.61M | $32.60M | $90.35M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $6.90M | $31.93M | $92.01M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.03M | $46.92M | $89.56M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $5.59M | $62.82M | $83.20M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.06M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |